Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Luminex; Qiagen; Life Technologies; AvanDx; Monogram Biosciences; and CombiMatrix

NEW YORK (GenomeWeb News) – Luminex this week announced that it has opened a new office in Shanghai, People's Republic of China, to serve as its center of operations in the Asia-Pacific region. The firm said that the office will include training lab space and a full-time staff, though it did not provide an expected number of employees. Luminex also has operations at its headquarters in Austin, Texas, and offices in Toronto and Oosterhout, The Netherlands.


Qiagen this week said that it had CE marked its next-generation KRAS test for colorectal cancer and has launched the assay. The firm said it is an updated version of its first pyrosequencing-based assay for personalized cancer treatment.


Life Technologies said this week that researchers at bioMérieux and the Institute of Analytical Sciences of the University of Lyon in France are using the AB SCIEX QTRAP 5500 System in a biomarker collaboration.


AdvanDx said this week that Memorial University Medical Center in Savannah, Ga., is using its PNA FISH tests to identify bloodstream pathogens one to three days earlier than conventional methods.


Monogram Biosciences said that it presented three studies at the American Society for Clinical Oncology meeting earlier this week that demonstrated the ability of its HERmark and VeraTag technologies in identifying distinct sub-populations of patients with HER-positive disease.


CombiMatrix said this week that researchers from its CombiMatrix Molecular Diagnostics subsidiary and from the University of Texas Health Science Center in San Antonio published a validation study on its HerScan array-based test in the journal Modern Pathology. The test facilitates subtyping of breast cancers into five different subtypes that are cytogenetically characteristic, CombiMatrix said.